PD166326

Cat. No.: HY-118144

CAS No.: 185039-91-2

Molecular Formula: $C_{21}H_{16}Cl_2N_4O_2$

Molecular Weight: 427.28

Target: BCRP; Src

Pathway: Membrane Transporter/Ion Channel; Protein Tyrosine Kinase/RTK

Storage: 4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (234.04 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.3404 mL	11.7019 mL	23.4039 mL
	5 mM	0.4681 mL	2.3404 mL	4.6808 mL
	10 mM	0.2340 mL	1.1702 mL	2.3404 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

PD166326 is a pyridopyrimidine-type inhibitor of receptor tyrosine kinases, with IC_{50}s of 6 nM and 8 nM for Src and Abl, respectively. PD166326 exhibits antileukemic activity[1][2].

IC_{50} & Target

IC50: 6 nM (Src), 8 nM (Abl)[1]

REFERENCES

[1]. Huron DR, et, al. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res. 2003 Apr;9(4):1267-73.

[2]. Wolff NC, et, al. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood. 2005 May 15;105(10):3995-4003.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA